S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 reasons to buy AMD before 2024
How does the Consumer Price Index affect the stock market?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
3 biotech powerhouses poised to thrive amid sector rebound
Broadcom falls into a buy-the-dip opportunity 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities

Design Therapeutics Stock Price, News & Analysis (NASDAQ:DSGN)

$2.43
+0.03 (+1.25%)
(As of 12/8/2023 ET)
Compare
Today's Range
$2.33
$2.44
50-Day Range
$1.99
$2.51
52-Week Range
$1.94
$10.72
Volume
190,346 shs
Average Volume
653,398 shs
Market Capitalization
$136.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67

Design Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
133.2% Upside
$5.67 Price Target
Short Interest
Bearish
9.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$49,350 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.30) to ($1.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

Medical Sector

636th out of 944 stocks

Pharmaceutical Preparations Industry

296th out of 443 stocks


DSGN stock logo

About Design Therapeutics Stock (NASDAQ:DSGN)

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. The company was incorporated in 2017 and is headquartered in Carlsbad, California.

DSGN Stock Price History

DSGN Stock News Headlines

Design Therapeutics Inc DSGN
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Design Therapeutics (NASDAQ: DSGN)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Why Is Design Therapeutics Stock Moving Lower Today?
DSGN - Design Therapeutics, Inc.
See More Headlines
Receive DSGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Design Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/12/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DSGN
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.67
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+133.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
7 Analysts

Profitability

Net Income
$-63,310,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$5.85 per share

Miscellaneous

Free Float
40,433,000
Market Cap
$136.08 million
Optionable
Not Optionable
Beta
1.62
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Pratik Shah Ph.D. (Age 53)
    Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
    Comp: $638.46k
  • Dr. Sean Jeffries Ph.D. (Age 43)
    Chief Operating Officer
    Comp: $572.21k
  • Dr. Aseem Z. Ansari Ph.D.
    Co-Founder & Scientific Advisor
  • Ms. Julie D. Burgess CPA
    Chief Accounting Officer
  • Dr. Elizabeth Gordon Ph.D.
    Senior Vice President of Regulatory Affairs
  • Dr. Jae B. Kim FACC (Age 53)
    M.D., Chief Medical Officer
  • Ms. Dawn Giangiulio
    Controller














DSGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Design Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Design Therapeutics in the last twelve months. There are currently 7 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DSGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSGN, but not buy additional shares or sell existing shares.
View DSGN analyst ratings
or view top-rated stocks.

What is Design Therapeutics' stock price target for 2024?

7 brokers have issued twelve-month price targets for Design Therapeutics' shares. Their DSGN share price targets range from $4.00 to $6.00. On average, they predict the company's share price to reach $5.67 in the next year. This suggests a possible upside of 133.2% from the stock's current price.
View analysts price targets for DSGN
or view top-rated stocks among Wall Street analysts.

How have DSGN shares performed in 2023?

Design Therapeutics' stock was trading at $10.26 on January 1st, 2023. Since then, DSGN shares have decreased by 76.3% and is now trading at $2.43.
View the best growth stocks for 2023 here
.

When is Design Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 12th 2024.
View our DSGN earnings forecast
.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) announced its quarterly earnings data on Monday, November, 13th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.14.

What ETFs hold Design Therapeutics' stock?

ETFs with the largest weight of Design Therapeutics (NASDAQ:DSGN) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).iShares Neuroscience and Healthcare ETF (IBRN).

When did Design Therapeutics IPO?

(DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include RTW Investments LP (4.49%), Principal Financial Group Inc. (1.28%), Walleye Capital LLC (0.67%), Assenagon Asset Management S.A. (0.44%), Prescott Group Capital Management L.L.C. (0.32%) and Charles Schwab Investment Management Inc. (0.31%). Insiders that own company stock include Arsani William, Deepa Prasad, Joao Md Siffert, Rodney W Lappe, Simeon George, Sr One Capital Fund I Aggregat and Stella Xu.
View institutional ownership trends
.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DSGN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -